We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Therapeutic Opportunities in Microplastic- and Nanoplastic-Associated Neuroinflammation A Mechanism-Guided Analysis of Drug Development, Repurposing, and New-Indication Opportunities
Summary
Tiny plastic particles from our environment may get into the body and trigger inflammation in the brain through several possible pathways, like stressing cells, weakening the brain's protective barrier, and disrupting gut-brain communication. This paper reviews existing research on these mechanisms, rather than presenting new experiments, and argues that understanding them could help scientists identify new drug targets or repurpose existing medications to protect brain health. It's important to note this is early-stage thinking: the biological pathways are plausible, but scientists still need more research to confirm how much microplastics actually affect human brain disease.
Microplastics and nanoplastics (MPs/NPs) can interact with biological systems through multiple mechanisms that may affect the central nervous system, including immune activation, blood-brain barrier dysfunction, oxidative stress, mitochondrial dysfunction, cytokine signaling, disrupted autophagy/proteostasis, neuronal injury, and gut-brain axis disruption. These pathways are biologically plausible, but links to human disease remain incomplete and require further study. From a therapeutic-development perspective, the key question is whether characterizing MP/NP-associated pathology can reveal actionable biological pathways. This creates opportunities for novel targets (where coverage is limited), drug repurposing (where existing agents already target the pathway), and indication expansion (where MP/NP-derived insights apply to other diseases sharing the same pathway). We outline a preliminary mechanism-guided landscape of MP/NP-associated neuroinflammatory biology and a framework for identifying these opportunities. Based on this analysis, Cythera Bio has prioritized two pathways for initial investigation, with others still under evaluation.